No Data
No Data
Tempest Therapeutics Struggles: A Financial Storm Brews Amidst Mounting Losses and Development Hurdles
Piper Sandler Keeps Their Buy Rating on Tempest Therapeutics (TPST)
Tempest Therapeutics (TPST) Receives a Buy From Scotiabank
Express News | HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Tempest FY23 EPS $(1.91) Vs $(3.09) YoY; Ended The Year With $39.2M In Cash And Cash Equivalents
Financial ResultsYear End 2023Tempest ended the year with $39.2 million in cash and cash equivalents, compared to $31.2 million on December 31, 2022. The increase was primarily due to proceeds from t
Tempest Therapeutics GAAP EPS of -$1.91 Beats by $0.03
No Data